Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma.
Verra N, Jansen R, Groenewegen G, Mallo H, Kersten MJ, Bex A, Vyth-Dreese FA, Sein J, van de Kasteele W, Nooijen WJ, de Waal M, Horenblas S, de Gast GC. Verra N, et al. Among authors: van de kasteele w. Br J Cancer. 2003 May 6;88(9):1346-51. doi: 10.1038/sj.bjc.6600915. Br J Cancer. 2003. PMID: 12778059 Free PMC article. Clinical Trial.
Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.
Luiten RM, Kueter EW, Mooi W, Gallee MP, Rankin EM, Gerritsen WR, Clift SM, Nooijen WJ, Weder P, van de Kasteele WF, Sein J, van den Berk PC, Nieweg OE, Berns AM, Spits H, de Gast GC. Luiten RM, et al. Among authors: van de kasteele wf. J Clin Oncol. 2005 Dec 10;23(35):8978-91. doi: 10.1200/JCO.2005.01.6816. Epub 2005 Oct 31. J Clin Oncol. 2005. PMID: 16260696 Clinical Trial.
Lack of anti-tumour reactivity despite enhanced numbers of circulating natural killer T cells in two patients with metastatic renal cell carcinoma.
Vyth-Dreese FA, Sein J, van de Kasteele W, Dellemijn TA, van den Bogaard C, Nooijen WJ, de Gast GC, Haanen JB, Bex A. Vyth-Dreese FA, et al. Among authors: van de kasteele w. Clin Exp Immunol. 2010 Dec;162(3):447-59. doi: 10.1111/j.1365-2249.2010.04274.x. Epub 2010 Oct 5. Clin Exp Immunol. 2010. PMID: 20942806 Free PMC article.
Selecting highly affine and well-expressed TCRs for gene therapy of melanoma.
Jorritsma A, Gomez-Eerland R, Dokter M, van de Kasteele W, Zoet YM, Doxiadis II, Rufer N, Romero P, Morgan RA, Schumacher TN, Haanen JB. Jorritsma A, et al. Among authors: van de kasteele w. Blood. 2007 Nov 15;110(10):3564-72. doi: 10.1182/blood-2007-02-075010. Epub 2007 Jul 27. Blood. 2007. PMID: 17660381 Free article.
Design and use of conditional MHC class I ligands.
Toebes M, Coccoris M, Bins A, Rodenko B, Gomez R, Nieuwkoop NJ, van de Kasteele W, Rimmelzwaan GF, Haanen JB, Ovaa H, Schumacher TN. Toebes M, et al. Among authors: van de kasteele w. Nat Med. 2006 Feb;12(2):246-51. doi: 10.1038/nm1360. Epub 2006 Feb 5. Nat Med. 2006. PMID: 16462803